Funding newsPublished November 1, 2026

ALLOX Raises $10.5M Seed Round

Recently funded · $10.5M SeedManufacturingESView source

Get the full ALLOX company profile

Access contacts, investors, buying signals & more

ALLOX, a Barcelona-based spin-off of the Centre for Genomic Regulation, has raised $10.5M in seed funding. Asabys Partners and ICF - Institut Català de Finances backed the round.

The company is built on technology and expertise from the lab of Ben Lehner, combining systematic mutagenesis, high-throughput phenotyping and biophysical modelling. Its immediate goal is to identify allosteric switches across all proteins, then use that resource to develop novel medicines for human diseases. Longer term, ALLOX aims to build tools to predict, design and engineer new protein functions. It is currently incubating at the Barcelona Biomedical Research Park (PRBB).

From the source

Grishin

ALLOX has closed a US$10.5 million (€9.4 million) seed round to expand its experimental and AI-enabled drug discovery platform. The Barcelona company maps functional sites in proteins to find new ways to tackle difficult-to-drug targets.

Its approach combines high-throughput genetics and biophysical measurements with predictive models. Rather than only identifying where a molecule binds, ALLOX studies how changes affect protein function, including allosteric sites that can influence activity from a different location. The financing will scale the platform and support proprietary AI models trained on its function-first datasets. I

Unlock the full source

CEO quotes, investor details and growth metrics

Start free trial